Physician

Gastroenterology

James Boyer practices Gastroenterology. He went to medical school at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is one of the top medical schools in the US. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He received 3 awards: "CMS Meaningful Use Stage 1 Certification", "Fellow (AGAF)" and "Elected Member". James Boyer is a published MD. He has 60 papers published. The most current publication "APC controls asymmetric Wnt/-catenin signaling and cardiomyocyte proliferation gradient in the heart."

Publications

---

• APC controls asymmetric Wnt/β-catenin signaling and cardiomyocyte proliferation gradient in the heart.
• The role of macrophage migration inhibitory factor (MIF) in autoimmune liver disease.
• Bile formation and secretion.
• Adult sea lamprey tolerates biliary atresia by altering bile salt composition and renal excretion.
• Fibrates as adjuvant therapy for chronic cholestatic liver disease - it's time has come.
• A Cholecystohepatic Shunt Pathway: Does the Gallbladder Protect the Liver?
• Harold O Conn Obituary.
• A c-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis.
• Elevated hepatic MRP3/ABCC3 expression in human obstructive cholestasis is mediated through TNF? and JNK/SAPK signaling pathway.
• Ost{alpha} Depletion Protects Liver from Oral Bile Acid Load.
• Drug-induced cholestasis.
• Oxidative stress and hepatic stellate cell activation are key events in arsenic induced liver fibrosis in mice.
• Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
• Small-duct sclerosing cholangitis associated with Schistosoma mansoni.
• Role of breast cancer resistance protein in the adaptive response to cholestasis.
• Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms.
• Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression.
• NHERF-1 binds to Mrp2 and regulates hepatic Mrp2 expression and function.
• The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease.
• Cholestasis: genetic and acquired.
• Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis.
• Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis.
• Arsenic (+ 3 oxidation state) methyltransferase and the methylation of arsenicals in the invertebrate chordate Ciona intestinalis.
• Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression.
• Hepatic uptake and biliary excretion of manganese in the little skate, Leucoraja erinacea.
• It's all about bile.
• ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained.
• OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids.
• Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II.
• Membrane trafficking of the human organic anion-transporting polypeptide C (hOATPC).
• Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases.
• The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution.
• Phloracetophenone-induced choleresis in rats is mediated through Mrp2.
• Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression.
• Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes.
• Hepatic and extrahepatic synthesis and disposition of dinitrophenyl-S-glutathione in bile duct-ligated rats.
• The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks.
• Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents.
• Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis.
• OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia.
• Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.
• Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?
• Liver biopsy: evolving role in the new millennium.
• Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis.
• The maintenance and generation of membrane polarity in hepatocytes.
• Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis.
• Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta.
• Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets.
• The Comparative Toxicogenomics Database (CTD).
• Bile salt transporters: molecular characterization, function, and regulation.
• Molecular characterization of a multidrug resistance-associated protein, Mrp2, from the little skate.
• Exploiting genome data to understand the function, regulation, and evolutionary origins of toxicologically relevant genes.
• A biliary milestone: functional expression of the human bile salt export pump.
• The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II.
• Unimpaired osmotic water permeability and fluid secretion in bile duct epithelia of AQP1 null mice.
• Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis.
• Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes.
• An evolutionarily ancient Oatp: insights into conserved functional domains of these proteins.
• Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions.

Schools

---

• Johns Hopkins University School Of Medicine

• New York Hospital

• Yale New Haven Hospital

• Yale

Doctors Specialties

---

• Internal Medicine
• Gastroenterology

Accepted Insurances

---

Awards

---

• CMS Meaningful Use Stage 1 Certification
• Fellow (AGAF)
• Elected Member

Education

---

• Yale-New Haven Hospital
• Johns Hopkins University
• New York Presbyterian Hospital - Cornell Campus
• Johns Hopkins University School of Medicine

Hospital

---

• Yale-New Haven Hospital

Drug Facts

---

NPI NUMBER		1447233267
NPPES Provider LastName		BOYER
NPPES Provider FirstName		JAMES
NPPES Provider ZIPCode		06510
NPPES Provider State		CT
Specialty Description		Gastroenterology
Total Claim Count		192.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1447233267
Last Name Of The Provider	BOYER
First Name Of The Provider	JAMES
View All

Similar Doctors

---

	Dr. Jacqueline K. Henchel, MD This Doctor is OpenDoctor Recommended.
	Dr. Shivi Sharma, MD This Doctor is OpenDoctor Recommended.
	Dr. Perry L. Miller, MD
	Dr. Elena Balica, MD This Doctor is OpenDoctor Recommended.
	Dr. Ashwini Bapat, MD
	Dr. Lorenzo Falchi, MD
	Dr. David N. Assis, MD This Doctor is OpenDoctor Recommended.
	Dr. Kenneth L. Marek, MD This Doctor is OpenDoctor Recommended.
	Dr. Vera W. Adanuvor, MD This Doctor is OpenDoctor Recommended.
	Dr. Priya A. Jamidar, MD This Doctor is OpenDoctor Recommended.
	Dr. Wajahat Z. Mehal, MD
	Dr. Theresa Lee, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog